Of the 1,194 Horizon 2020 proposals received between 2014 and 2017, most were related to the development of IVDs, while a third were focused on personalized medicine.
The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million in EU funding to develop a lung cancer assay.
Several companies will receive grants to develop hepatitis C molecular point-of-care and core antigen diagnostic assays.
The firm aims to have its test on the European clinical market by early next year, followed by a launch in the US.
The firm will use the grant to expedite the development of tests to identify more than 25 bacterial pathogens and antibiotic resistance markers in whole blood samples.
According to project organizers, feasibility testing in the first phase of the project was successful and clinical trials are planned for later this year.
The device being developed will interpret the scattered patterns of light that has passed through the body to enable cellular-level imaging and will compete with biopsies and blood tests.
The test would also be used to detect antibiotic susceptibility. Fraunhofer received £900,000 from SBRI Healthcare in support of the project to develop the test.
The Codex4SMEs project, which has a €3.1 million budget, involves seven countries to increase cooperation in Europe's northwest region to develop companion diagnostics.
Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.